Peripheral Nerve Injury Clinical Trial
Official title:
1-2 Phase of Safety and Efficacy of Patient Intraneural Injections of VEGF165 Plasmid Gene Therapy on Regeneration After Total Severance or Disruption of the Entire Nerve Fiber
The purpose of this study is to determine safety and efficacy of pl-vegf165 ("Neovasculgen") for regeneration of peripheral nerve. Pl-vegf165 ("Neovasculgen") is the permitted in Russian Federation angiogenic medication that induce growth of new vessels and included in a complex therapy for patients with peripheral arterial diseases in Russia. It has also been shown to enhance nerve regeneration and muscle reinnervation in animals but these properties have not previously been studied in patients. Moreover, currently there is no method in clinical use to speed the rate of recovery after nerve injury. The objective of this study is to explore the ability of pl-vegf165 to benefit the treatment of patients with peripheral nerve injury. The investigators hypothesize that treatment with intraneural injections with pl-vegf165 after peripheral nerve reconstruction will accelerate nerve regeneration, reduce the period of denervation and improve muscle reinnervation and recovery in patients with peripheral nerve injury.
Status | Not yet recruiting |
Enrollment | 45 |
Est. completion date | September 2017 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Patients with confirmed transection injury between shoulder and wrist - Isolated injury of ulnar or median nerve (not mixed injury of several nerves) - Nerve injuries which are amenable to direct end-to-end repair - Length of the gap between of stumps of transected nerve no longer than 3,5 centimeters - Early delayed (secondary) repair performed between 2 to 6 weeks after nerve injury Exclusion Criteria: - Length of the gap between of stumps of transected nerve more than 3,5 centimeters - Simultaneous injury of several peripheral nerves - Localization of nerve injury beyond of forearm - Presence of neurological deficit preceding to nerve injury - Systemic disease of connective tissue - Myopathy - Large surgical procedures planned for next one and a half year - Presence of oncological diseases - Pregnancy and breastfeeding - Alcohol and drug addiction - Patient ability to adhere strictly to the rules of the current clinical trial protocol |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Human Stem Cell Institute, Russia | Kazan Federal University, Russia |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disabilities of the Arm, Shoulder and Hand (DASH) Measure | The Disabilities of the Arm, Shoulder and Hand (DASH) Outcome Measure is a 30-item, self-report questionnaire designed to measure physical function and symptoms in patients with any or several musculoskeletal disorders of the upper limb. The questionnaire was designed to help describe the disability experienced by people with upper-limb disorders and also to monitor changes in symptoms and function over time. Testing has shown that the DASH performs well in both these roles. | 540 days | No |
Primary | Adverse events | 540 days | Yes | |
Secondary | Medical Research Council (MRC) Scale for Muscle Strength | In this scale, muscle strength is graded on a scale from 0 to 5 depending on ability to make whole fall active range of motion and presence of muscle resistance | 90 days;180 days; 270 days; 360 days; 450 days; 540 days | No |
Secondary | The Short Form (36) Health Survey | The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. | 90 days;180 days; 270 days; 360 days; 450 days; 540 days | No |
Secondary | Nerve conduction velocity | For electrodiagnostic assessment, nerve conduction velocity (NCV) was tested as motor and sensory. The results categorized according to the Yale sensory scale and the severity of sensation and function of the nerves was scored as follows: 0, no sensation; 1, decreased or abnormal sensation; 2, normal sensation. | 180 days; 360 days; 540 days | No |
Secondary | Electromyography | For an EMG, a needle electrode was inserted through the skin into the muscle which injured nerve supplied. The presence, size and shape of the waveform registered and the ability of the muscle to respond when the nerves were stimulated. Also these results scored as follows: 0, no activity; 1, few or single movement; 2, partial activity; 3, full activity. | 180 days; 360 days; 540 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02359825 -
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
|
Phase 1 | |
Not yet recruiting |
NCT02865317 -
Cortical Effects of Peripheral Nerve Injury At Birth
|
N/A | |
Recruiting |
NCT01554722 -
Needle Nerve Contact in Ultrasound Guided Femoral Block
|
N/A | |
Recruiting |
NCT06071988 -
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
|
Phase 3 | |
Recruiting |
NCT06071936 -
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
|
Phase 3 | |
Recruiting |
NCT05541250 -
Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation in Severe Peripheral Nerve Injury (PNI)
|
Phase 1 | |
Recruiting |
NCT06209632 -
Mirror Therapy Combined With Contralaterally Controlled Functional Electrical Stimulation for Peripheral Nerve Injury
|
N/A | |
Completed |
NCT01116362 -
Comparing Primary With Secondary Repair of Based on Electrodiagnostic Assessment and Clinical Examination
|
Phase 2 | |
Withdrawn |
NCT04270019 -
Polyethylene Glycol to Improve Sensation Following Digital Nerve Laceration
|
Phase 1/Phase 2 | |
Completed |
NCT01302275 -
Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain
|
Phase 4 | |
Terminated |
NCT01088256 -
Efficacy of Etoricoxib on Peripheral Hyperalgesia
|
Phase 2 | |
Completed |
NCT02228928 -
Study of Capsaicin Patch for the Management of Peripheral Neuropathic Pain
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00950391 -
Enhancement of Functional Recovery After Peripheral Nerve Injury With Tacrolimus
|
Phase 1/Phase 2 | |
Completed |
NCT00953277 -
Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
|
Phase 4 | |
Not yet recruiting |
NCT06003166 -
4-AP Peripheral Nerve Crossover Trial
|
Phase 3 | |
Not yet recruiting |
NCT02666456 -
The Influence of Sensory Phenotype on the Risk of Developing Neuropathic Pain
|
N/A | |
Terminated |
NCT02034461 -
Micro-Electrodes Implanted in a Human Nerve
|
N/A | |
Completed |
NCT01596491 -
Study of Possible Changes in QST After Application of Capsaicin on Patients With Peripheral Neuropathic Pain
|
N/A | |
Recruiting |
NCT03147313 -
Extracorporal Shock Wave Treatment to Improve Nerve Regeneration
|
N/A |